News

The bosutinib positive CHMP opinion is concerned with the conditional marketing authorization in the European Union for the treatment of different phases of philadelphia chromosome positive chronic myelogenous

Phase 1 trial, being conducted in the US, Canada and Denmark, will assess the most favorable KPT-330 dose to treat advanced hematologic malignancies. Karyopharm founder, chief scientific officer

The technology will be evaluated in refolding difficult to express microbial products that are expressed as inclusion bodies, under the agreement. BaroFold CSO and Founder Matthew Seefeldt said,

The acquisition aims to provide better quality diagnostic services to community patients in British Columbia, Canada, through patient service centers, homecare and long-term care visits, and dedicated laboratory

The medication is indicated for acromegaly and pituitary gigantism patients who cannot undergo surgical therapies or who do not considerably respond to surgical therapies. Teijin Pharma president Kentaro

APN311 is a monoclonal chimeric antibody developed to treat neuroblastoma, a malignant tumor developing from nerve tissue and most common in children below five years. Paladin Labs interim

Xencor has received an undisclosed amount as the milestone payment from Janssen for the use of Xtend antibody technology platform. Xencor president and CEO Bassil Dahiyat said, "There

Prism is an electronic data capture (EDC) solution, which is designed to streamline the initiation and management of clinical trials. During the Connectathon demonstration, Prism will facilitate live

Under the collaboration, Mobile MedSoft’s Helix Pharmacy System customers will now gain access to Mevesi’s software to analyze the data and gain a better understanding of their business.